Trial Profile

A Phase 2 Study of Intralesional PV-10 in the Treatment of Metastatic Melanoma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rose bengal sodium (Primary)
Indications Malignant melanoma
Focus Therapeutic Use
Sponsors Provectus Biopharmaceuticals

Most Recent Events

27 Sep 2021 According to Provectus Biopharmaceuticals media release, data from this study will be presented on two poster presentations at the SMR 2021 Congress (the Society for Melanoma Research annual meeting).
01 Oct 2014 According to company's website, results published in the Annals of Surgical Oncology (Title- Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma).
29 Sep 2014 Data from overall analysis and sub-group data were announced in Provectus biopharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com